Phase 4 N=1,564 Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change
Healthy
Primary: Local AEs — 500; 344; 186; 189 injections
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=280 Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)
Multiple Sclerosis
Primary: Percentage of Participants With No or Minimal Decline in Cognitive Function, Defined As an Improved or Stable Symbol Digit Modalities Test (SDMT) Score or a Decline of 4…
Phase 4 N=46 Erector Spinae Plane Block Versus Conventional Analgesia in Complex Spine Surgery
Opioid Use · Pain, Postoperative
Primary: Intraoperative and Postoperative Opioid Consumption — 191; 139.4 MME/day
Phase 4 N=124 Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Week 16 in the Percentage of Time in Range [70 to 180 Milligram Per Deciliter (mg/dL)] — 26.22 percentage of time
Phase 4 N=75 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 62 Participants
Phase 4 N=50 Low Dose Ketamine for Blunt Thoracic Trauma
Blunt Injury of Thorax · Multiple Rib Fractures, Involving Three Ribs
Primary: Milligrams of Morphine Equivalents (MME) Administered — 84.9; 81.7 Morphine Milligam Equivalents (MME)
Phase 4 N=8 Pharmacokinetics of JULUCA in Hemodialysis
HIV/AIDS · ESRD
Primary: Dolutegravir (DTG) Ctau — 1259; 1666 ng/mL
Phase 4 N=85 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
Giant Cell Tumor of Bone
Primary: Number of Participants Experiencing Adverse Events (AEs) of Interest (EOI) — 3; 0; 6; 1 Count of Participants
Phase 4 N=41 Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
Secondary Progressive Multiple Sclerosis
Primary: Percentage of Participants Achieving Seroconversion One Week After Receiving Second Vaccine (EAS) — 52.9; 75.0; 90.0 percentage of participants
Phase 4 N=39 Study to Determine Safety and Dosage of OPTISON in Pediatric Participants
Transthoracic Echocardiography · Suspected or Known Structural or Functional Cardiac Abnormality
Primary: Mean Total Visualization Score of Qualitative Endocardial Border Delineation (EBD) of the 12 Segments of the Left Ventricle (LV) Wall in Standard Apical 4-chamber (A4C)…
Phase 4 N=41 Cognitive Functions After TIVA With Dexmedetomidine
Postoperative Confusion
Primary: Mini Mental State Examination (MMSE) Score at the Second Hour After Surgery — 27.40; 26.45 scores on a scale
Phase 4 N=4 Ropivacaine Plasma Concentrations and Pharmacokinetics Following Erector Spinae Plane Block in the Pediatric Population
Anesthesia, Local
Primary: Ropivacaine Concentrations — 0; 0; 1232.25; 850.25 ng/mL
Phase 4 N=136 Otrivine: Quality of Life (QoL) Impact in a Real-World Setting
Common Cold
Primary: Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score — 75.8; -1.5; -15.4; -27.3 score on a scale — p=0.2968
Phase 4 N=1 Ulipristal for Endometriosis-related Pelvic Pain
Endometriosis
Primary: Pelvic Pain — 3.5; 0.2; 3.9 units on a scale — p=<0.05
Phase 4 N=30 OTC Naproxen and Acetaminophen Anti-Inflammatory Action in Dental Implant Patients
Osseointegrated Dental Implantation · Pain, Acute
Primary: Pain Intensity Scores on Numeric Pain Intensity Scale 0-6 Hours — 1; 3 score on a scale — p=<0.05